Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232514 | 0.86 | KIF11 (0.42) | KIF11MMP2 | |
| SCHEMBL23125118 | 0.86 | KIF11 (0.47) | KIF11KCNN4 | |
| SCHEMBL23125119 | 0.86 | KIF11 (0.47) | KIF11KCNN4 | |
| SCHEMBL21998928 | 0.85 | KIF11 (0.37) | KIF11 | |
| SCHEMBL5053673 | 0.82 | KIF11 (0.45) | KIF11KCNN4HTR2AHTR2CADRA1A | |
| SCHEMBL15761360 | 0.80 | KIF11 (0.42) | KIF11KCNN4 | |
| SCHEMBL28773128 | 0.77 | KIF11 (0.40) | KIF11KCNN4HTR2AHTR2CADRA1A | |
| SCHEMBL18326682 | 0.77 | KIF11 (0.61) | KIF11 | |
| SCHEMBL12694858 | 0.77 | KIF11 (0.61) | KIF11 | |
| SCHEMBL17083023 | 0.77 | KIF11 (0.61) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9731035-B2 | Method of imaging osteoarthritis using a folate conjugate | PURDUE RESEARCH FOUNDATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-1904183-B1 | Pharmaceutical composition for the treatment of osteoarthritis | PURDUE RESEARCH FOUNDATION (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8765096-B2 | Methods and compositions for treating and diagnosing kidney disease | ENDOCYTE, INC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140065066-A1 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | PURDUE RESEARCH FOUNDATION (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130266964-A1 | METHOD OF DETECTING ENDOTHELIAL PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | LEAMON CHRISTOPHER PAUL (US) | 2012-10-25 | — | — | US | disclosed |
| US-20100226967-A1 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100104626-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090214636-A1 | Imaging and Therapeutic Method Using Monocytes | LOW PHILIP S | 2009-08-27 | — | — | US | disclosed |
| WO-2008101231-A2 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1904183-A2 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | Purdue Research Foundation (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007139815-A2 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070009434-A1 | Imaging and therapeutic method using monocytes | PURDUE RESEARCH FOUNDATION | 2007-01-11 | — | — | US | disclosed |
| WO-2007006041-A2 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | PURDUE RESEARCH FOUNDATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226967-A1 | IMAGING AND THERAPEUTIC METHOD USING PROGENITOR CELLS | CD44, MYADM, ANTXR2 | KIF11 2419/4885KCNN4 3841/4885HTR2A 4820/4885 |
| US-20100104626-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | VDR, GC, CYP24A1 | KIF11 1543/4885KCNN4 2236/4885HTR2A 4656/4885 |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | VDR, GC, CYP24A1 | KIF11 1543/4885KCNN4 2236/4885HTR2A 4656/4885 |
| US-20090214636-A1 | Imaging and Therapeutic Method Using Monocytes | CD14, MYADM, CD68 | KIF11 1528/4885KCNN4 4055/4885HTR2A 4450/4885 |
| US-20070009434-A1 | Imaging and therapeutic method using monocytes | CD14, MYADM, CD68 | KIF11 1528/4885KCNN4 4055/4885HTR2A 4450/4885 |
| US-20140065066-A1 | IMAGING AND THERAPEUTIC METHOD USING MONOCYTES | CD14, MYADM, CD68 | KIF11 1528/4885KCNN4 4055/4885HTR2A 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.